Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.10.2012 | Original Scientific Paper | Ausgabe 5/2012

European Surgery 5/2012

Effects of everolimus on hepatic ischemia/reperfusion injury in an experimental rat model

European Surgery > Ausgabe 5/2012
M.D. Dr. B. G. Demirci, Prof. Dr. M. Cindoruk, U. T. Yilmaz, M. D. Demirag, I. I. Gonul, U. Demirci, O. Gulbahar, Prof. Dr. A. Dalgic
Wichtige Hinweise
An erratum to this article can be found at http://​dx.​doi.​org/​10.​1007/​s10353-013-0215-y.



The current study is the first to evaluate the protective effect of everolimus on biochemical and histopathological features with an experimental hepatic ischemia reperfusion (I/R) injury model.


Twenty-four Wistar Albino rats were randomized into four groups: Group 1 (sham group) was subjected to laparotomy. Group 2 (I/R group) was subjected to ischemia for 1 hour and reperfusion for 24 hours without treatment. Group 3 was treated with 1.5 mg/kg/day everolimus perorally for 7 days without performing I/R. Group 4 was treated with 1.5 mg/kg/day everolimus perorally for 7 days followed with performing I/R. Blood samples and liver tissues were obtained to assess serum aspartate aminotransferase (AST), alanin aminotransferase (ALT), albumin, tumor necrosis factor-alpha (TNFα), interleukin-6 (IL-6) and tissue malonyl dialdehyde (MDA), and superoxide dismutase (SOD) levels and histopathologic examination.


Serum AST and ALT levels of I/R group were significantly higher than sham group. Serum transaminase levels were significantly decreased after treatment with everolimus (group 4) when compared with I/R group (group 2). TNFα and MDA levels were decreased; however, SOD levels were increased in group 4. The sham group and group 3 showed normal histological findings. Morphologic analysis showed reduced degrees of injury in group 4 than group 2 with regards to cholestasis, sinusoidal dilatation, congestion, hydropic degeneration, and subcapsular necrosis.


This is the first report as regards everolimus attenuates biochemical and histopathological alterations of hepatic I/R injury. Everolimus can be a choice for preventing I/R injury during liver transplantation surgery in the future besides its well-known immunosuppressive property.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 5/2012

European Surgery 5/2012 Zur Ausgabe